Literature DB >> 11739846

Spontaneous remission in canine myasthenia gravis: implications for assessing human MG therapies.

G D Shelton1, J M Lindstrom.   

Abstract

The natural course of autoimmune canine MG was determined in 53 dogs with muscular weakness and a positive acetylcholine receptor antibody titer. Dogs were treated with anticholinesterase therapy, without immunosuppression. Spontaneous clinical and immunologic remission occurred in 47 of 53 dogs within an average of 6.4 months. Neoplasia was identified in the six dogs that did not spontaneously remit. This study questions the value of using canine MG in studies designed to assess the effect of immunotherapies.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11739846     DOI： 10.1212/wnl.57.11.2139

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  12 in total

1.  Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue.

Authors:  F Shawn Galin; Cheryl L Chrisman; James R Cook; Likang Xu; Patricia L Jackson; Brett D Noerager; Nathaniel M Weathington; J Edwin Blalock
Journal:  Brain Behav Immun       Date:  2006-11-20       Impact factor: 7.217

2.  Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity.

Authors:  Jie Luo; Palmer Taylor; Mario Losen; Marc H de Baets; G Diane Shelton; Jon Lindstrom
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

3.  Acquired myasthenia gravis in a poodle.

Authors:  Danielle Richardson
Journal:  Can Vet J       Date:  2011-02       Impact factor: 1.008

4.  How clinical trials of myasthenia gravis can inform pre-clinical drug development.

Authors:  Anna Rostedt Punga; Henry J Kaminski; David P Richman; Michael Benatar
Journal:  Exp Neurol       Date:  2015-01-13       Impact factor: 5.330

5.  Total laryngectomy for management of chronic aspiration pneumonia in a myopathic dog.

Authors:  Karen M Vernau; Stanley L Marks; Maggie A Kuhn; William T N Culp; Tammy J Owens; G Diane Shelton; Tausif Siddiqui; Rachel Pollard; Peter C Belafsky
Journal:  Can Vet J       Date:  2016-07       Impact factor: 1.008

Review 6.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

Review 7.  Current management options in myasthenia gravis.

Authors:  Stephen Reddel
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

8.  Acute idiopathic polyradiculoneuritis concurrent with acquired myasthenia gravis in a West Highland white terrier dog.

Authors:  Gabriela Dumitrita Stanciu; Gheorghe Solcan
Journal:  BMC Vet Res       Date:  2016-06-14       Impact factor: 2.741

Review 9.  Diagnosis and Treatment of Lower Motor Neuron Disease in Australian Dogs and Cats.

Authors:  A M Herndon; A T Thompson; C Mack
Journal:  J Vet Med       Date:  2018-08-06

10.  Risk Factors and Outcomes in Cats with Acquired Myasthenia Gravis (2001-2012).

Authors:  D W Hague; H D Humphries; M A Mitchell; G D Shelton
Journal:  J Vet Intern Med       Date:  2015-08-26       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.